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Aim: Persistent airway inflammation with mucus retention in patients with chronic airway
disorders such as COPD and bronchiectasis may lead to frequent exacerbations, reduced lung
function and poor quality of life. This study investigates if long-term humidification therapy
with high flow fully humidified air at 37 C through nasal cannulae can improve these clinical
outcomes in this group of patients.
Method: 108 patients diagnosed with COPD or bronchiectasis were randomised to daily humid-
ification therapy or usual care for 12 months over which exacerbations were recorded. Lung
function, quality of life, exercise capacity, and measures of airway inflammation were also re-
corded at baseline, 3 and 12 months.
Results: Patients on long-term humidification therapy had significantly fewer exacerbation days
(18.2 versus 33.5 days; pZ 0.045), increased time to first exacerbation (median 52 versus 27
days; p Z 0.0495) and reduced exacerbation frequency (2.97/patient/year versus 3.63/
patient/year; pZ 0.067) compared with usual care. Quality of life scores and lung function
improved significantlywith humidification therapy comparedwith usual care at 3 and 12months.OPD, chronic obstructive pulmonary disease; ECCS, European Community for Steel and Coal; ECG,
atory volume in 1 s; FiO2, fraction of inspired oxygen; FVC, forced vital capacity; HRCT, high-reso-
iratory capacity; ICS, inhaled corticosteroids; LABA, long acting beta 2 agonists; LTHT, long-term
rm oxygen therapy; MRC, Medical Research Council; 6MWD, 6min walk distance; PEEP, positive end
ife; SaO2, oxygen saturation; SGQR, St George’s respiratory questionnaire; TREAT, treatment group.
2760066.
dlemore.co.nz (L. Jayaram).
0 Elsevier Ltd. All rights reserved.
526 H. Rea et al.Conclusion: Long-term humidification therapy significantly reduced exacerbation days,
increased time to first exacerbation, improved lung function and quality of life in patients with
COPD and bronchiectasis.
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ª 2010 Elsevier Ltd. All rights reserved.Table 1 Baseline patient characteristics and inflamma-
tory profile.
TREAT CON
COPD/bronchiectasis 34/26 29/19
Sex: M/F 31/29 27/21
Ethnicity: E/M/P/O 33/13/12/2 30/6/7/5
Age (yrs) 66.2 (9.5) 69.0 (11)
Respiratory admissions
in previous year
0.73 (1.22) 0.58 (1.00)
Non, ex/smoker 16/44 8/40
Pack years 24.6 (20.9) 36 (26.0)
ICS, %a 78.3% 85.7%
LABA, % 51.7% 41.7%
Tiotropium, % 13.3% 14.6%
Atrovent, % 21.7% 22.9%
Regular prednisone, % 18.3% 12.5%
Regular, cyclical
antibiotics, %
20.0% 12.5%
BMI (kg m2) 27.8 (5.3) 27.5 (5.9)
Dyspnoea (MRC scale) 2.82 (0.91) 2.86 (0.98)
FEV1 (L) 1.17 (0.58) 1.16 (0.42)
FEV1 (% of pred) 44.7 (20.7) 45.3 (14.7)
FVC (L) 1.91 (0.70) 2.03 (0.76)
FVC (% of pred) 59.6 (20.1) 62.5 (18.7)
FEV1/FVC (%) 61.3 (18.8) 59.9 (15.9)
IC (L) 1.71 (0.72) 1.72 (0.69)
6MWD (m) 356 (134) 336 (117)
SGRQ symptoms 55.3 (23.0) 57.4 (22.1)Introduction
Chronic obstructive pulmonary disease (COPD) and bron-
chiectasis are both airway disorders characterised by
neutrophilic airway inflammation, mucus hypersecretion
and retention, and impaired mucociliary transport.1e5
Difficulty clearing mucus from the lungs is a feature of
both disorders and results in recurrent infective exacer-
bations and a subsequent decline in lung function and
QOL.2,6
A number of treatment strategies to improve mucociliary
clearance have been employed. These include physical
methods7 and mucoactive drugs, such as mannitol, which
have been shown to improve mucus clearance and health-
related QOL.8,9 Recently there has been increasing evidence
that humidification therapy may increase mucociliary
clearance, reduce mucus viscosity and aid expectoration in
airway diseases. Hasani and colleagues demonstrated that as
few as 3 h/day of humidification therapy over seven days for
bronchiectasis patients significantly increased lung muco-
ciliary clearance measured by radioaerosol labelling.10 Mall
and colleagues demonstrated in a mouse model that airway
surface dehydration leads to persistent neutrophilic airway
inflammation with increased mucus production and resultant
emphysema.11 Taken together, these studies suggest that
airway surface dehydration may play an important role in
the pulmonary damage associated with chronic airway
disorders. However, the effects of long-term humidification
therapy (LTHT) in patients with chronic airways disorders are
currently unknown.
Thus, the aim of this 12-month randomised study was to
examine the effects of LTHT on frequency of exacerba-
tions, QOL, lung function, exercise capacity and airway
inflammation in patients with bronchiectasis or COPD, two
chronic airway disorders associated with mucus production
and recurrent chest infections. Based on the work discussed
above, we hypothesised that LTHT would reduce exacer-
bations and improve physiological outcomes and QOL in
patients with chronic airways disease.SGRQ impact 39.7 (18.2) 37.2 (18.0)
SGRQ activity 63.7 (20.4) 66.3 (20.2)
SGRQ total score 49.6 (16.0) 49.4 (16.6)
TCC, 106/mgb 22.4 (23.3) 18.6 (27.1)
Viability 77.0 (21.2) 78.9 (21.4)
Eosinophil count, %b 1.16 (2.52) 2.65 (3.98)
Neutrophil count, % 64.3 (23.0) 66.9 (19.9)
Macrophage count, % 20.4 (8.8) 20.6 (11.2)
Lymphocyte count, % 0.16 (0.44) 0.41 (0.49)
Abbreviations: Ethnicity: European/Maori/Pacific/Other, MRC
ScaleeMedical Research Council Dyspnoea Scale, 6MWDe 6 min
walk distance, SGRQ e St George’s Respiratory Questionnaire.
a % of subjects using the medication.
b Continuous data are given as mean (SD) except median (IQR).Methods
Participants
One hundred and eight (108) patients with COPD or bron-
chiectasis were recruited from hospital admission or
outpatient clinics over the period of a year. The study group
represented diverse ethnic groups (Table 1). The study
received approval from the local Ethics Committee and was
conducted in accordance with the Declaration of Helinski
International Conference on Harmonization (ICH)/Good
Clinical Practice, with patients giving written consent.A clinical diagnosis of COPD was confirmed with
spirometry and defined as an FEV1 of less than 70% of pre-
dicted, an FEV1/FVC ratio < 70% without significant bron-
chodilator reversibility.12 Bronchiectasis was confirmed by
high-resolution computed tomography (HRCT).13 Patients
with bronchiectasis associated with cystic fibrosis or hypo-
gammaglobulinaemia were excluded. All patients were
The clinical utility of long-term humidification therapy 527required to have a history of 2 or more exacerbations in the
previous 12 months and daily sputum production greater
than 5 ml. Participants were recruited when stable with no
sign of an exacerbation for at least 4 weeks. Regular, daily
or cyclical, oral antibiotics and prednisone were not
exclusion criteria.
All patients were under the care of a respiratory
physician at entry into the study and were managed
according to best practice Australasian clinical guidelines.
Patients started trial treatments once their respiratory
status was considered optimal by their respiratory
physician.Study design
This was a prospective, single centre, open labelled,
randomised, two parallel group, placebo-controlled trial.
Diary cards were used, exacerbations were counted, and
patients were also assessed at baseline, 3 and 12 months
(Fig. 1).Ran
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Figure 1 Study deOutcomes
The primary outcome was the rate of exacerbations per
patient over their treatment period. Secondary outcomes
included the time to first exacerbation, the number of
exacerbated days and hospital admissions, change in QOL
measures, lung function, 6 min walk test and inflammatory
markers (sputum cell counts) over the 12 months.
Procedures
Patients attended a preliminary assessment visit where
spirometry and reversibility were measured. This was fol-
lowed within two weeks by the first assessment visit (base-
line). Medications current at the time of enrolment were
recordedbut not adjusted norwithdrawn. Dyspnoeawas self-
rated using the Medical Research Council (MRC) Scale.14 Vital
signs (heart rate and blood pressure) and an electrocardio-
gram (ECG) were performed at each visit. Spirometry was
performed with a MicroLab ML3500 spirometerdomised
 = 108) 
USUAL CARE
(CON) n = 48 
47 completed 3-month assessment
1 withdrew:
1 unwell.
43 completed 12-month assessment
4 withdrew:
2 died – COPD. 
1 moved region. 
1 diary cards too labour-intensive. 
d for eligibility 
 = 127)
sign and profile.
528 H. Rea et al.(Micromedical) according to ATS/ERS guidelines15 using
European Community for Steel and Coal (ECCS) predicted
values.16 Exercise capacity was assessed with the 6 min walk
distance test (6MWD) performed according to ATS Guide-
lines.17 Quality of life was assessed with the self-reported St
George’s Respiratory Questionnaire (SGRQ).18 Total scores
vary from 0 (no disability) to 100 (maximum disability), with
a change of 4 units considered to be clinically meaningful.19
Compliance was measured electronically by the humidifica-
tion device and the information downloaded at 2-month
intervals. A sputum sample was obtained spontaneously if
possible, or, if FEV1 was>30% of predicted, sputum induction
was performed and processed according to published
guidelines.20
Definition of exacerbations
Exacerbations were event based, and defined as a wors-
ening of 2 or more respiratory symptoms for 2 or more days
that required treatment with antibiotics or oral predni-
sone.21 If the period between resolution of symptoms and
a further worsening exceeded 7 days, it was considered to
be a new exacerbation. Diary cards were examined retro-
spectively and exacerbations counted by 3 adjudicators
blinded to treatment. Hospital admission data were avail-
able for the study period and the 12 months preceding the
start of the study. Respiratory symptoms (cough, sputum
volume, sputum colour and dyspnoea) were recorded by the
patients in daily diary cards, assessed using a 5-point Likert
scale. These recordings were used to define baseline
respiratory symptoms and establish exacerbations based on
changes from baseline.
Treatment intervention
Humidified air, fully saturated at 37 C at a flow rate of 20e
25 L/min was delivered via Optiflow nasal cannulae con-
nected to a MR880 humidifier and HC210 flow source system
(Fisher and Paykel Healthcare, New Zealand) (Fig. 2). This
heated pass-over humidifier produces gas phase humidifi-
cation and has a heated breathing tube to minimise
condensation. When used at moderate airflows of approxi-
mately 25 L/min, the system delivers positive end expiratoryFigure 2 Photograppressure (PEEP) in the vicinity of 1e3 cm H2O.
22 The PEEP
generated is considered to decrease the number of breaths
per minute and consequently increase tidal volume and
reduce dead space.23 Patients were instructed to use the
equipment for 2 or more hours per day in their home. Two
hours was chosen a priori by the investigators as a compro-
mise between the short study of Hasani10 demonstrating
mucociliary clearance with 3 h of daily use over one week,
and a minimum time period considered reasonable and
practical for daily long-term use. Individual flow rates,
either 20 or 25 L/min, were set to the flowmost preferred by
the patient. For patients on long-term oxygen therapy
(LTOT), the oxygen supply was connected into the humidi-
fied air stream and adjusted so that the patient maintained
the same SaO2. The study was performed in Auckland, New
Zealand over a 12-month period encompassing the four
seasons of the year.
Statistical analysis
Sample size
Sample size calculation was based on the primary outcome
of exacerbation frequency (number of exacerbations per
patient per year). Assuming a median rate of 2.92,2
a sample size of 50 patients per group was required to
achieve 80% power to detect a rate in the intervention
group 20% lower than control at the 5% level of significance.
The LTHT group size was increased to 60 to potentially
account for an increased rate of attrition.
Data analysis
An intention to treat analysis was performed using all avail-
able data. The comparison of responses of the two groups
(TREAT or CON) was done in the generalised linear model
framework, allowing inclusion of demographic variables
(gender, ethnic group, age), disease type, number of respi-
ratory admissions in previous year, and pre-treatment cova-
riatewhere available. Survival analysis of the time to the first
exacerbation included the same explanatory variables.
Summary values are expressed using raw (baseline) or
model adjusted (least square) means. Results for the
exacerbation endpoints are expressed as model predictedh of LTHT device.
Figure 3 KaplaneMeier plot for time to first exacerbation.
The clinical utility of long-term humidification therapy 529means with 95% confidence intervals. All statistical tests
were two-tailed, with a p-value of <0.05 considered as
statistically significant.
Results
Patient characteristics at baseline by group are shown in
Table 1. The study profile and reasons for withdrawal are
given in Fig. 1.
Exacerbations
Exacerbation frequency was 3.63/patient/year in the CON
group and 2.97 in the TREAT group (pZ 0.067), a reduction
to 81.8% of control (Table 2). The number of exacerbation
days was 33.5/patient in the CON group and 18.2 in the
TREAT group (p Z 0.045) a reduction to 54.3% of control.
Similarly, median time to first exacerbation was 27 days in
the CON group and 52 days in the TREAT group (pZ 0.0495)
(Fig. 3). More TREAT (12/60Z 20.0%) than CON patients (4/
48 Z 8.3%) exhibited no exacerbations at all during study
(p Z 0.043). Mean MRC dyspnoea scores were similar
between groups at 12 months (TREAT 2.49, CON 2.54,
p Z 0.518), largely unchanged from baseline (Table 1).
Hospital admissions
In the 12 months prior to the study, respiratory-related
admissions per year were similar in both groups: TREAT
0.73/year, CON 0.58/year. Results over the study period
were TREAT 0.39/year and CON 0.47/year (p Z 0.439).
Changes in lung function
At enrolment, both TREAT and CON patient groups had
moderate to severe impairment, with mean FEV1 % pre-
dicted of 44.7% and 45.3% respectively (Table 1). At 3
months significant differences favouring TREAT were
evident for FEV1, FEV1 % predicted, FVC and FVC % pre-
dicted, and these significant improvements in lung function
persisted at 12 months (Figs. 4 and 5). At 12 months FEV1
had improved by 0.12 L and FVC by 0.28 L. Both FEV1/FVC
ratio and IC were similar for both groups at baseline (Table
1), and did not alter significantly at 3 or 12 months.
Health-related quality of life
The SGRQ total score was similar for both groups at base-
line, TREAT 49.6 units and CON 49.4 units respectively, andTable 2 Exacerbation endpoints.
TREAT CON
Frequency #/patient/year 2.97 3.63
Annual exacerbation
days (geometric mean)
18.2 33.5
Days to 1st exacerbation
(predicted median)
52 27
a Hazard ratio.
b Confidence interval.indicated poor health status (Table 1). At 3 and 12 months
the baseline-adjusted symptoms and total score both
differed significantly in favour of the TREAT group
compared to the CON group (Fig. 5), with all four scores
showing differences above 5.9 units at 12 months (symp-
toms, 8.3; activity, 5.9; impacts, 6.9; total, 6.8).
Changes in exercise capacity
The mean walking distance for the TREAT group decreased
by 14.1 m (4.0%) from baseline and by 29.0 m (8.6%) for the
CON group (pZ 0.485). The rate of decline in 6MWD in the
TREAT group was inversely correlated with the improve-
ment in FVC over the 12-month study period (r Z 0.31,
pZ 0.03).
Inflammatory markers
The sputum cell count profile was similar for both groups at
baseline, with a neutrophilic predominance (Table 1), and
did not alter significantly at 3 or 12months (data not shown).
Pharmacological therapy
Overall medication use was similar between TREAT and
CON groups at baseline, and except for antibiotic use,
during the study. Nearly 80% of subjects were on regular
ICS, 40e50% on LABA, and 22% on anticholinergic therapy
(Table 1). Analysis of both steroid and antibiotic use as
recorded by patients on the daily diary cards during the
study showed similar rates of prednisone use in both
groups, and significantly lower antibiotic use in the TREAT
group expressed as the percentage of diary days per
patient in which use was recorded (prednisone: TREAT,p-Value Ratio 95% CIb of ratio
0.067 0.818 (0.660, 1.014)
0.045 0.544 (0.300, 0.985)
0.050 0.650a (0.423, 0.999)
Figure 4 Plots of lung function variables at baseline, 3 and 12 months.
530 H. Rea et al.17.7%; CON, 16.0%; p Z 0.765, antibiotic: TREAT 22.8%;
CON, 38.5%; p Z 0.008)
Compliance
Eighty percent of all TREAT participants (48/60) used the
device for an average of at least 1 h/day and 32% (19/60)Figure 5 Plots of quality of life variaused it for at least 2 h/day. The mean use/day/patient was
1.6 h (SD Z 0.67).
Adverse events
No serious adverse events defined as ocular, oropharyngeal,
cardiac, respiratory, gastrointestinal, or dermatologicalbles at baseline, 3 and 12 months.
The clinical utility of long-term humidification therapy 531side effects related to the therapy were reported during
the study.
Patient satisfaction
When questioned at study completion, 41 (77%) patients of
the remaining 53 in the TREAT arm (see Fig. 1) were satis-
fied with LTHT therapy and wished to continue using it
daily. For the 12 patients not wanting to continue there
were three reasons: poor compliance during the trial but
agreed to complete only the 12 months trial period (nZ 4);
non-medical issues impacting compliance, e.g. shifting
location (n Z 4), and non-respiratory medical issues
affecting compliance (n Z 4).
Discussion
This is the first study examining the long-term effects of
high flow humidification therapy in patients with bronchi-
ectasis and COPD. Although a previous study has shown one
week of high flow humidification therapy could improve
lung mucociliary clearance in bronchiectactic patients, it
was unknown whether LTHT would be tolerated, complied
with, and ultimately efficacious in a compromised pop-
ulation with chronic airways disease. Our data demonstrate
that averaging as little as 1e2 h/day of LTHT decreased the
number of exacerbation days and increased the time to first
exacerbation. Significant improvements were also noted in
lung function and QOL scores with LTHT. In the discussion
that follows we assess the impact of these findings,
examine potential mechanisms of action of LTHT, and
explore the limitations in our study design.
LTHT is an effective treatment for chronic airways
disease
While LTHT reduced two clinical aspects of exacerbations,
namely the number of exacerbation days and the time to
first exacerbation, it did not quite significantly reduce the
exacerbation frequency, the primary outcome (pZ 0.067).
However, given the strong trend favouring LTHT (2.97 versus
3.63 events/year) we posit that the study was slightly
underpowered for this outcome, for several reasons.
Firstly, we observed a slightly lower (18.2%) than antici-
pated reduction (20% was used in sample sizing) in exacer-
bation frequency with LTHT treatment. Secondly, losses to
follow-up were similar for the two treatment groups, but
higher than anticipated for the CON group, resulting in
imbalance that affected study power. Lastly, and perhaps
most importantly, whereas exacerbation frequency is
considered to be a key outcome measure in the clinical
assessment and management of patients with COPD and
bronchiectasis, it is an extremely difficult endpoint to
measure accurately. Several recent commentaries, and our
own experience, have highlighted the pitfalls associated
with quantifying exacerbation frequency and severity.24,25
Thus the sample size calculated a priori for exacerbation
frequency from published data may have been under-
estimated. In the context of significant improvements
noted in the number of exacerbated days, time to first
exacerbation, lung function and QOL, we consider that thestrong trend in reduced exacerbation frequency is consis-
tent with a therapeutic benefit of LTHT in patients with
chronic airways disease. This is also supported by the
analysis showing lower TREAT group antibiotic use
(p Z 0.008) as recorded on the diary cards used in deter-
mining exacerbations.
The results found with LTHT are also quantitatively
similar to previous reports using medical therapy in patients
with chronic airways diseases. For example, inhaled corti-
costeroids (ICS), a mainstay of airway treatment, alone or in
combination with long acting beta 2 agonists (LABA), and
the long acting anticholinergic bronchodilator, tiotropium,
have been shown to reduce exacerbation rates by 15e25%,
decrease the rate of decline in lung function, and improve
QOL significantly in patients.26,27 The reduction in exacer-
bation rate by 18.2% with LTHT in our study is within this
range of improvement seen with best practice medical
therapy. Furthermore, the significant improvements in FEV1
reported here are similar to that achieved with combination
inhaler therapy in patients with COPD.26
Mechanisms of action of LTHT
There are several mechanisms by which LTHT may improve
outcomes in chronic airways disease: LTHT may cause
a decrease in airway inflammation. Sputum cell counts,
however, did not alter over time in either the TREAT or CON
groups, suggesting that LTHTwas unlikely to reduce airway
inflammation. Consistent with the short-term humidifica-
tion study of Hasani10 LTHTmay lead to improved outcomes
through enhanced lung mucociliary clearance. This is sup-
ported physiologically by the parallel improvement in FEV1
with FVC in the treatment group, without change in the
FEV1/FVC ratio. This suggests that LTHT may improve small
airway function and reduce lung gas trapping by improving
mucociliary clearance. Other possibilities include the
mechanical effects of PEEP which slows down the rate of
breathing, and airflows of 20e25 L/min which may improve
gas exchange by providing washout of dead space.28,23
However within the context of the current treatment trial,
insights into mechanisms by which LTHT can improve
outcomes remain speculative.
Limitations of study
Although there are unavoidable limitations to the current
treatment study, there are also strengths that should be
acknowledged. The therapy occurred over a continuous 12-
month period, was tested against a control of ‘standard
care’, and was reported with an intention to treat analysis.
The use of three blinded assessors for adjudicating exac-
erbations avoided bias, and the statistical analysis of
exacerbation rate was implicitly time-weighted, providing
conservative estimates.24 Assessments were made at both 3
and 12 months, demonstrating repeatable and sustained
improvements in outcomes.
Nevertheless, there are also several potential weak-
nesses in the study. Firstly, there could not be a placebo
treatment indistinguishable from LTHT. Sham (placebo)
humidification therapy for the usual care group was
considered, but no placebo therapy could be designed that
532 H. Rea et al.was undetectable to the patient. A system consisting of
high flow nasal delivery of 37 C air at ambient humidity
levels without water vapour added was considered likely to
have a detrimental effect on patients by drying their upper
airways.
Secondly, active treatment compliance did not meet the
initial design goals. It averaged 1.6 h/day rather than the
expected 2 h/day over the 12-month treatment period.
Compliance time per day is a factor in a 12-month study.
Tsolaki and colleagues found 45% of patients offered
treatment refused to commit to 5 h non-invasive ventilation
treatment per day over a year.29
A third possible limitation to our study was the inclusion
of patients with either COPD or bronchiectasis. Although
COPD and bronchiectasis are two distinct disorders with
different aetiologies, they have similarities: both are
chronic airway disorders characterised by neutrophilic
inflammation and increased mucus secretion. Furthermore,
patients with COPD may have co-existent bronchiectasis,
noted to be 29% in one study.30 For entry into this study
patients needed to have symptoms of two or more exac-
erbations in the previous year, and also be producing >5 mL
of sputum per day. The rationale was that LTHT would
improve mucociliary clearance for both patient groups,
resulting in improved patient outcomes. Since the trial was
not designed for subgroup analysis, future trials will be
necessary to determine if efficacy of LTHT differs between
patients with COPD and with bronchiectasis.
In summary, LTHT averaging 1e2 h/day resulted in
significant improvements in exacerbation days, time to first
exacerbation, lung function and QOL, in patients with COPD
and bronchiectasis. The therapy was well tolerated, had no
related adverse events, and the majority of patients opted
to continue with the treatment at the conclusion of the 12-
month trial period. Further studies, more disease specific,
with longer daily treatment time by including overnight
use, and physiological studies are recommended to confirm
and extend our results and to gain insight into underlying
mechanisms of LTHT in chronic airway disease.Acknowledgement
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